Pharma CSO

The Pipeline
Paradox

127 programs. $2.1B invested. 3% will reach patients. Can you show your board where the value is actually hiding in your pipeline?

Your R&D Pipeline Value Distribution

Where $66.8B in potential NPV is concentrated across 208 programs

Discovery
2-4 years
127programs
$0.8B NPV
85% attrition
$254M
invested
Preclinical
1-2 years
42programs
$2.1B NPV
70% attrition
$630M
invested
Phase I
1-2 years
18programs
$4.5B NPV
50% attrition
$450M
invested
Phase II
2-3 years
11programs
$8.2B NPV
60% attrition
$935M
invested
Phase III
3-4 years
6programs
$18.7B NPV
40% attrition
$2,100M
invested
Filed/Approved
1-2 years
4programs
$32.5B NPV
$200M
invested
208
Total Programs
$66.8B
Total NPV
$4.6B
Total Investment
3.1%
Success Rate
Pipeline ROI: $66.8B NPV ÷ $4.6B invested = 1462% return potential (probability-weighted)
$2.6B
average cost to develop one drug
3.2%
discovery-to-approval success rate
12 years
average development timeline
90%
of Phase I drugs never reach market

From Pipeline Complexity to Portfolio Clarity

Without SlideStrike

  • Pipeline data scattered across 50 spreadsheets
  • NPV calculations inconsistent by program
  • Board sees project lists, not value distribution
  • No visual connection between stage and risk
  • Hours preparing pipeline updates

With SlideStrike

  • Single funnel view of entire pipeline
  • Standardized, probability-weighted NPV by stage
  • Board sees exactly where value concentrates
  • Attrition and investment visually linked
  • Real-time pipeline presentations in minutes

SlideStrike for R&D Pipeline Intelligence

Transform pipeline complexity into strategic clarity

Pipeline Funnel
Programs and value by stage
Attrition Tracker
Historical success rates by phase
NPV Calculator
Risk-adjusted value per program
TA Concentration
Portfolio balance by therapy area
Milestone Timeline
Key decision points visualized
Scenario Modeler
What-if portfolio analysis

Pipeline Strategy Questions

QWhat is the pipeline paradox in pharma R&D?

The pipeline paradox refers to the tension between high R&D investment and low success rates. Despite spending $2.6B+ per approved drug, only 3% of discovery programs reach market, creating valuation uncertainty.

QHow does SlideStrike help CSOs visualize pipeline value?

SlideStrike creates dynamic funnel visualizations showing program counts, NPV by stage, attrition rates, and investment allocation - turning complex portfolio data into board-ready insights.

QWhat metrics should a CSO track for pipeline health?

Key metrics include programs per stage, risk-adjusted NPV, phase transition rates, therapeutic area concentration, time-to-milestone, and R&D productivity ratios.

QHow do investors evaluate pharma pipelines?

Investors look at pipeline breadth, stage distribution, competitive positioning, patent cliffs, and probability-weighted NPV. Clear visualization directly impacts market valuation.

QCan SlideStrike model different pipeline scenarios?

Yes, SlideStrike enables what-if modeling showing how different attrition rates, partnership deals, or development timelines affect total portfolio value.

See Where Your Pipeline Value Hides

Most CSOs discover new insights about their portfolio within 10 minutes of their first SlideStrike session.

Visualize Your Pipeline